خدمة ببتيدات cGMP

مُصمَّم للأبحاث البيولوجية والتطبيقات الصناعية، وغير مخصص للأغراض السريرية أو الطبية الفردية.

دعم تصنيع الببتيدات وفق متطلبات GMP لبرامج التطوير السريري والتجاري.

مناقشة المشروع

شاركنا التسلسل المستهدف والنقاء والحجم والتعديلات وصيغة التسليم ومتطلبات التوثيق. ستراجع Quantai الجدوى وترد بمسار تسعير عملي.

اطلب عرض سعر

القدرات الأساسية

ضبط عمليات GMP وتتبع الدفعات

Under a GMP quality system every batch has a record that can be followed backwards: which lot of each raw material and resin was used, which equipment, which operator, which in-process checks were run and what they returned. Deviations from the approved procedure are recorded and assessed rather than corrected silently, and changes to a validated process go through a controlled change procedure. The practical effect for a customer is that a question about a batch delivered a year ago has a documented answer.

دعم التوسيع والتحقق والتوثيق

Moving a process from development to a GMP batch is a documentation exercise as much as a chemistry one. Analytical methods are validated for the parameters they are used to judge, the process is described in a form that can be executed the same way twice, and the resulting records are assembled into a package suitable for regulatory review. The work needed depends on the stage the programme is at, so it is scoped per project.

أنظمة جودة متوافقة مع المسارات الخاضعة للتنظيم

Peptide manufacture for regulated use sits under ICH Q7, the guidance for active pharmaceutical ingredients. That shapes how materials are qualified, how in-process controls are set, how out-of-specification results are investigated and how long records are retained. Which elements apply to a given programme depends on how far it has progressed, and is confirmed at the outset rather than assumed.

استمرارية توريد طويلة الأمد لشركاء B2B

A supply relationship for a regulated product needs more than a first successful batch. It needs the same process to give the same result over time, which means controlling raw material sources, keeping methods stable, and managing change so that improvements do not quietly alter the product. Requirements around forecast, lead time and batch size are agreed per programme.

سير العمل النموذجي

1مراجعة المتطلبات

2الجدوى الفنية

3عرض السعر والجدول الزمني

4التخليق أو تنفيذ العملية

5وثائق مراقبة الجودة

6الشحن والمتابعة

مرحلة التطوير	دعمنا في مجال الببتيدات
المفهوم والجدوى	استراتيجية تصميم الببتيدات وتحسين التسلسل وتقييم الجدوى
أبحاث الاكتشاف	تخليق ببتيدات مخصص وتصميم ببتيدات موجِّهة ودعم الفحص الوظيفي
تحسين المركّب الرائد	تعديل الببتيدات واستراتيجية الاقتران وتحسين العلاقة بين البنية والوظيفة
تطوير العمليات	تحسين المسار ومتانة العملية واستراتيجية ضبط الشوائب
التصنيع وفق GMP	تخليق ببتيدات متوافق مع GMP وتوثيق للجودة ودعم الإفراج عن الدفعات

ملاحظات تقنية

What GMP covers, and what it does not

GMP is a system for making product consistently and being able to show it, not a certificate attached to a molecule. It governs premises and equipment, qualification of materials and suppliers, written procedures, training, in-process control, release testing against a specification, and record retention. It does not by itself say what the specification should be. That is set by the programme and its regulatory pathway, and it is why a specification discussion has to happen before a GMP batch is planned.

Specification and release testing

A peptide API specification typically covers appearance, identity by mass spectrometry and often by amino acid analysis, purity and individual impurities by HPLC, peptide content, water content by Karl Fischer titration, residual solvents by gas chromatography, counter-ion content, and where relevant bioburden, endotoxin and sterility. Each parameter needs a method, an acceptance criterion and a justification for both. Deciding this list is part of the project rather than a standard form.

Analytical method validation

Methods used to release material are validated for the characteristics they are relied on for: specificity, linearity, range, accuracy, precision, detection and quantitation limits, and robustness. A purity method that cannot separate a known related substance from the main peak is not fit for release regardless of how precise it is, so the impurity profile of the actual process drives what the method has to resolve.

Stability and storage

Stability studies under ICH Q1A conditions establish how long material meets its specification and under what storage conditions. For lyophilised peptides the parameters that usually move first are water content, purity and, where a sequence contains susceptible residues, specific degradation products such as oxidised methionine or deamidated asparagine. Study design and time points are agreed with the programme's requirements in view.

Documentation package

What accompanies a GMP batch is agreed in advance and typically includes the certificate of analysis, executed batch record summary, analytical raw data, method validation reports where applicable, and a statement of the materials used. Support for regulatory filings, including drug master file arrangements, is discussed per programme.

ما تحصل عليه

GMP batch manufactured against an agreed specification
Certificate of analysis with results for each specified parameter
Batch record documentation and material traceability
Analytical method and validation documentation as scoped
Stability data where the programme requires it

التطبيقات النموذجية

Preclinical and toxicology supply — Material for studies where identity, purity and impurity profile need to be documented well enough to support later comparison with clinical batches.

Clinical trial material — API supply where the specification, methods and records have to withstand regulatory review, and where batch-to-batch comparability matters.

Commercial supply — Continuing manufacture of a validated process, with change control keeping the product consistent across the life of the programme.

Second-source qualification — Establishing an alternative supply route for a peptide already in production elsewhere, including comparability work against the incumbent material.

الأسئلة الشائعة

At what stage should a programme move to GMP material?

Usually when the material will be used in a study whose data has to support a regulatory submission. Moving earlier costs more than necessary; moving later risks having to repeat work because the earlier material cannot be shown to be comparable. The decision is specific to the programme and its intended pathway.

What is the difference between GMP grade and high purity?

They answer different questions. Purity describes the material. GMP describes the system that produced it and the evidence that it was produced as intended. A very pure peptide made outside a quality system is still not GMP material, because there is no controlled record of how it came to be.

Who sets the specification?

It is agreed between the customer and the manufacturer, informed by the intended use, the regulatory pathway, and the impurity profile the process actually produces. A specification written without reference to the real process tends either to be unachievable or to control the wrong things.

Can you support a regulatory filing?

Documentation support, including arrangements around drug master files, is scoped per programme. What is needed differs considerably between an early-stage submission and a commercial application, so it is discussed rather than offered as a fixed package.

How is comparability between batches demonstrated?

By testing against the same specification with the same validated methods, and by comparing the impurity profile rather than only the headline purity figure. Two batches can both meet a 98 percent purity criterion while differing in which impurities make up the remainder, and it is that difference that comparability work is designed to detect.

What quality documentation comes with a batch?

The certificate of analysis is standard. Batch record summaries, analytical raw data, method validation reports and stability data are included according to what the programme requires, and that list is agreed before manufacture rather than after.